You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Financial news, mergers and acquisitions, partnerships, and alliances.
The company's RT-PCR/MALDI-TOF test comprises five assays designed to detect the N, ORF1, and ORF1ab regions of the SARS-CoV-2 genome.
Shares of the Boulder, Colorado-based firm will begin trading on the Nasdaq today under ticker symbol "BDSX" at $18 per share.
Qiagen said that growth in the quarter was primarily driven by COVID-19 testing products and improving customer demand for other products.
University spinout PercayAI will analyze genomic and clinical data from WUSTL's McDonnell Genome Institute in search of potential coronavirus drug combinations.
The company's acquisitions of Thrive Early Detection and Base Genomics are meant to accelerate its development of a liquid biopsy multi-cancer screening test.
Kaiser Health News reports San Francisco and Alameda counties in California are no longer using Verily Life Sciences' COVID-19 testing program, but a Verily spokesperson says it currently working with multiple Bay Area counties.
The New York Times reports that developers in New York City are increasingly interested in life science spaces.
A UK study has found that antibodies against SARS-CoV-2 may decline over time, Reuters reports.
In PNAS this week: genetic and epigenetic variation in individuals with diabetic kidney disease, spontaneous genetic alterations in Saccharomyces cerevisiae, and more.